The study and its comparison
HATS randomized 160 patients with coronary disease and low HDL to simvastatin plus niacin, antioxidant vitamins, both regimens, or placebos for three years. Researchers assessed coronary narrowing and cardiovascular events. [1]
The antioxidant mixture did not significantly improve the angiographic comparison with placebo. Adding it attenuated a selected HDL-subfraction response to simvastatin-niacin. [1]
What the finding establishes
The mixture design cannot identify vitamin C as the cause of that interaction. Small groups and an older treatment context also limit current medication decisions. Complete funding and conflicts were not established from the abstract. This is not a reason to stop prescribed therapy or avoid vitamin C in foods; it illustrates why supplement combinations need their own evidence. [1]
A hypothetical distinction
Imagine a four-ingredient mixture changes a drug response. Naming one ingredient as responsible requires a separate comparison.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.